{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:21:18Z","timestamp":1783938078672,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012299","name":"Warren Alpert Medical School of Brown University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012299","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL46716"],"award-info":[{"award-number":["R01HL46716"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL128831"],"award-info":[{"award-number":["R01HL128831"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["T32HL160517"],"award-info":[{"award-number":["T32HL160517"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["1F32HL160063-01"],"award-info":[{"award-number":["1F32HL160063-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56HL133624-05"],"award-info":[{"award-number":["R56HL133624-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jss.2024.09.065","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T10:22:57Z","timestamp":1729506177000},"page":"600-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Sodium-Glucose Cotransporter-2 Inhibition Normalizes Metabolic Derangements in the Ischemic Myocardium"],"prefix":"10.1016","volume":"303","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6457-2663","authenticated-orcid":false,"given":"Christopher","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Broadwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharif A.","family":"Sabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Bellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghamsh","family":"Kanuparthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ruhul","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-801X","authenticated-orcid":false,"given":"Frank W.","family":"Sellke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2024.09.065_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101622","article-title":"Global cardiovascular diseases death rate prediction","volume":"48","author":"Gaidai","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jss.2024.09.065_bib3","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jss.2024.09.065_bib5","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jss.2024.09.065_bib6","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/CIRCULATIONAHA.111.033126","article-title":"Reasonable incomplete revascularization","volume":"123","author":"Dauerman","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jss.2024.09.065_bib7","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.cjca.2011.07.007","article-title":"Management of patients with refractory angina: Canadian cardiovascular society\/Canadian pain society joint guidelines","volume":"28","author":"McGillion","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jss.2024.09.065_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009002","article-title":"Therapeutic approaches for the no-option refractory angina patient","volume":"14","author":"Povsic","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jss.2024.09.065_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl Med Commun"},{"key":"10.1016\/j.jss.2024.09.065_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jss.2024.09.065_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCRESAHA.117.311565","article-title":"Translational research in cardiovascular repair","volume":"122","author":"Chamuleau","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jss.2024.09.065_bib13","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jss.2024.09.065_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018245","article-title":"Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes","volume":"98","author":"Zou","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jss.2024.09.065_bib15","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jss.2024.09.065_bib16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2024.09.065_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2024.09.065_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2024.09.065_bib19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2024.09.065_bib20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2024.09.065_bib21","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jss.2024.09.065_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","article-title":"The pathophysiology of heart failure","volume":"21","author":"Kemp","year":"2012","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.jss.2024.09.065_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in\u00a0vivo myocardial ischemia\u2013reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.jss.2024.09.065_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","article-title":"SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jss.2024.09.065_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/JOE-17-0457","article-title":"Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury","volume":"236","author":"Tanajak","year":"2018","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jss.2024.09.065_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00395-019-0733-2","article-title":"Inhibition of sodium\u2013glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization","volume":"114","author":"Baker","year":"2019","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jss.2024.09.065_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure","volume":"14","author":"Santos -Gallego","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jss.2024.09.065_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028623","article-title":"Canagliflozin improves myocardial perfusion, fibrosis, and function in a swine model of chronic myocardial ischemia","volume":"12","author":"Sabe","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jss.2024.09.065_bib29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.surg.2011.07.022","article-title":"High-fat diet\u00a0alters prostanoid balance and perfusion in ischemic myocardium of naproxen-treated swine","volume":"150","author":"Chu","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.jss.2024.09.065_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017437","article-title":"Effects of high fat versus normal diet on extracellular Vesicle\u2013induced angiogenesis in a swine model of chronic myocardial ischemia","volume":"10","author":"Aboulgheit","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jss.2024.09.065_bib31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00395-011-0200-1","article-title":"Therapeutic neovascularization for coronary disease: current state and future prospects","volume":"106","author":"Lassaletta","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jss.2024.09.065_bib32","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.2174\/1381612811319270003","article-title":"Cardiac dysfunction and oxidative stress in the metabolic syndrome: an Update on antioxidant therapies","volume":"19","author":"Ilkun","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jss.2024.09.065_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/14791641211047135","article-title":"Impaired subendocardial perfusion in patients with metabolic syndrome","volume":"18","author":"Fantin","year":"2021","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jss.2024.09.065_bib34","article-title":"A chronic cardiac ischemia model in swine using an ameroid constrictor","volume":"128","author":"Keeran","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jss.2024.09.065_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.30754","article-title":"Time to benefit of sodium-glucose cotransporter-2 inhibitors among patients with heart failure","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jss.2024.09.065_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/DMSO.S184437","article-title":"Canagliflozin review \u2013 safety and efficacy profile in patients with T2DM","volume":"12","author":"Jakher","year":"2019","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.jss.2024.09.065_bib37","doi-asserted-by":"crossref","first-page":"H108","DOI":"10.1152\/ajpheart.2001.280.1.H108","article-title":"Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique","volume":"280","author":"Reinhardt","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jss.2024.09.065_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jss.2024.09.065_bib39","article-title":"Clinical applications of pressure-volume assessment in congenital heart disease","volume":"2","author":"Hiremath","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"10.1016\/j.jss.2024.09.065_bib40","first-page":"H1279","article-title":"Development of coronary collateral circulation in left circumflex Ameroid-occluded swine myocardium","volume":"253","author":"Roth","year":"1987","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jss.2024.09.065_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48716-y","article-title":"Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus","volume":"13","author":"Kuo","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jss.2024.09.065_bib42","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jss.2024.09.065_bib43","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00125-020-05359-2","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia\u2013reperfusion injury: a meta-analysis","volume":"64","author":"Sayour","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.jss.2024.09.065_bib44","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2022.03.353","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction","volume":"79","author":"Udell","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jss.2024.09.065_bib45","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/cvr\/cvab075","article-title":"Alternative strategies in cardiac preclinical research and new clinical trial formats","volume":"118","author":"Kreutzer","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jss.2024.09.065_bib46","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.159.10.1104","article-title":"Clustering of metabolic factors and coronary heart disease","volume":"159","author":"Wilson","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jss.2024.09.065_bib47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.14740\/cr507w","article-title":"The prevalence of metabolic syndrome in coronary artery disease patients","volume":"7","author":"Montazerifar","year":"2016","journal-title":"Cardiol Res"},{"key":"10.1016\/j.jss.2024.09.065_bib48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.mca.0000065744.52558.9f","article-title":"Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease","volume":"14","author":"Solymoss","year":"2003","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jss.2024.09.065_bib49","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/postmj\/qgad008","article-title":"Prevalence of metabolic syndrome in the United States national health and nutrition examination survey 2011\u201318","volume":"99","author":"Liang","year":"2023","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jss.2024.09.065_bib50","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3390\/ijerph18041773","article-title":"Metabolic syndrome and coronary artery disease risk: a meta-analysis of observational studies","volume":"18","author":"Alshammary","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jss.2024.09.065_bib51","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4103\/2230-8210.139238","article-title":"Association of metabolic syndrome with severity of coronary artery disease","volume":"18","author":"Mahalle","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jss.2024.09.065_bib52","doi-asserted-by":"crossref","first-page":"H428","DOI":"10.1152\/ajpheart.00283.2008","article-title":"Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation","volume":"296","author":"Sodha","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jss.2024.09.065_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12944-019-1171-8","article-title":"Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review","volume":"19","author":"Yao","year":"2020","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jss.2024.09.065_bib54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00395-012-0243-y","article-title":"Overfed Ossabaw swine with early stage metabolic syndrome have normal coronary collateral development in response to chronic ischemia","volume":"107","author":"Lassaletta","year":"2012","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jss.2024.09.065_bib55","doi-asserted-by":"crossref","first-page":"H2558","DOI":"10.1152\/ajpheart.01198.2007","article-title":"High-fat diet-induced obesity leads to increased NO sensitivity of rat coronary arterioles: role of soluble guanylate cyclase activation","volume":"294","author":"Jebelovszki","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jss.2024.09.065_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110103","article-title":"Angiogenesis in obesity","volume":"126","author":"Nijhawans","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jss.2024.09.065_bib57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/cvr\/cvp276","article-title":"Critical role of complex III in the early metabolic changes following myocardial infarction","volume":"85","author":"Heather","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jss.2024.09.065_bib58","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jss.2024.09.065_bib59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jss.2024.09.065_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-023-04663-y","article-title":"The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice","volume":"6","author":"Choi","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.jss.2024.09.065_bib61","article-title":"Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: a systematic review and meta-analysis","volume":"26","author":"Rivera","year":"2023","journal-title":"Am Heart Hournal Plus"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480424006292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480424006292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T04:47:16Z","timestamp":1732078036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480424006292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":58,"alternative-id":["S0022480424006292"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2024.09.065","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter-2 Inhibition Normalizes Metabolic Derangements in the Ischemic Myocardium","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2024.09.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}